Horizon Therapeutics (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 02/17/21
Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and OutcomesBusiness Wire • 02/04/21
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021Business Wire • 02/03/21
UPDATE: Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billionMarket Watch • 02/01/21
Horizon Therapeutics to acquire Viela Bio in deal with equity value of $3.05 billionMarket Watch • 02/01/21
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine PortfolioBusiness Wire • 02/01/21
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (pegloticase injection) TrialsBusiness Wire • 01/11/21
Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/22/20
Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine ProductionBusiness Wire • 12/17/20
Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions EducationBusiness Wire • 12/03/20
Horizon Therapeutics (HZNP) Down 6.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/02/20
Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International CommunitiesBusiness Wire • 11/30/20
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® TechnologyBusiness Wire • 11/23/20